Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Oriol Sola-Morales"'
Autor:
Elaine Julian, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, Wolfgang Greiner, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Antonella Cardone, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Objectives Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealin
Externí odkaz:
https://doaj.org/article/49b7e3fc8c3140c6be0c21e052b00350
Autor:
Elaine Julian, Fabrizio Gianfrate, Oriol Sola-Morales, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Objectives We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide ‘additional benefit’ compared to the status quo of many parallel independent national and s
Externí odkaz:
https://doaj.org/article/2ba07948754a4eed9306acaeee9a8759
Autor:
Eduard Vrdoljak, Joseph Gligorov, Lieve Wierinck, PierFranco Conte, Jacques De Grève, Françoise Meunier, Carlo Palmieri, Luzia Travado, Andrew Walker, Theresa Wiseman, Rachel Wuerstlein, Emilio Alba, Concepción Biurrún, Rosanna D’Antona, Oriol Sola-Morales, Catherine Ubaysi, Roberta Ventura, Fatima Cardoso
Publikováno v:
Breast, Vol 55, Iss , Pp 79-90 (2021)
People with metastatic breast cancer face many challenges and disparities in obtaining optimal cancer care. These challenges are accentuated in underserved patient populations across Europe, who are less likely to receive quality healthcare for reaso
Externí odkaz:
https://doaj.org/article/1c3d87f05720487dbcad8a94472a532b
Autor:
Mathias Flume, Marc Bardou, Stefano Capri, Oriol Sola-Morales, David Cunningham, Lars-Ake Levin, Maarten J. Postma, Nicolas Touchot
Publikováno v:
Journal of Market Access & Health Policy, Vol 6, Iss 1 (2018)
Background: The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a vari
Externí odkaz:
https://doaj.org/article/4051883c446b407d91b5a131413948f4
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:913-918
Drug reimbursement decisions that spark public controversy are potential signals that processes used to reach such decisions do not adequately reflect society's goals. Such controversial decisions appear to be a characteristic of Quality-Adjusted Lif
Autor:
Oriol Sola‐Morales, Lesley H. Curtis, Julien Heidt, Laura Walsh, Deborah Casso, Susan Oliveria, Patrick Saunders‐Hastings, Yufei Song, Tiffany Mercado, Robbert Zusterzeel, Vera Mastey, James Harnett, Ruben G. W. Quek
Publikováno v:
Clinical Pharmacology & Therapeutics.
Autor:
Lesley H. Curtis, Oriol Sola‐Morales, Julien Heidt, Patrick Saunders‐Hastings, Laura Walsh, Deborah Casso, Susan Oliveria, Tiffany Mercado, Robbert Zusterzeel, Rachel E. Sobel, Jessica J. Jalbert, Vera Mastey, James Harnett, Ruben G. W. Quek
Publikováno v:
Clinical Pharmacology & Therapeutics.
Autor:
Domenico, Moro, Michael, Schlander, Harry, Telser, Oriol, Sola-Morales, Michael David, Clark, Andrew, Olaye, Charlotte, Camp, Mohit, Jain, Thomas, Butt, Sumeet, Bakshi
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:581-598
Conventional cost-effectiveness analysis [CEA] using cost per QALY thresholds may counteract other incentives introduced to foster development of treatments for rare and ultra-rare diseases. Therefore, alternative economic evaluation methods were exp
Autor:
Jürgen Wolf, Jacoline C. Bouvy, Oriol Sola-Morales, Richard H. Chapman, Andrew Briggs, Carsten Bokemeyer, Jennifer G. Gaultney, Alexander J Upton, Stacey Kowal
Publikováno v:
Applied Health Economics and Health Policy. 19:625-634
The arrival of precision oncology is challenging the evidence standards under which technologies are evaluated for regulatory approval as well as for health technology assessment (HTA) purposes. Several key concepts are discussed to highlight the sou
Autor:
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Publikováno v:
Health Research Policy and Systems, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background The European Regulation on Health Technology Assessment (EU HTA R), effective since January 2022, aims to harmonize and improve the efficiency of common HTA across Member States (MS), with a phased implementation from January 2025
Externí odkaz:
https://doaj.org/article/660c1c179a5f4b32bace34cbb01905ab